

019664-000400US

March 3, 2000

DIALOG(R) File 351:DERWENT WPI

(c) 2000 Derwent Info Ltd. All rts. reserv.

010644483

WPI Acc No: 96-141437/199615

XRAM Acc No: C96-044525

Increasing immunogenicity of antigen by interaction with vector particle
 - having solid hydrophilic core and outer layer of fatty acid or
 phospholipid, useful in vaccines, esp. against cytomegalovirus

Patent Assignee: BIOVECTOR THERAPEUTICS SA (BIOV-N); INSERM INST NAT SANTE
 & RECH MEDICALE (INRM)

Inventor: BETBEDER D; DAVIGNON J; DAVRINCHE C; PRIEUR E; DAVIGNON J L

Number of Countries: 022 Number of Patents: 007

Patent Family:

Patent No	Kind	Date	Applicat No	Kind	Date	Main IPC	Week
FR 2723849	A1	19960301	FR 9410479	A	19940831	A61K-039/00	199615 B
WO 9606638	A1	19960307	WO 95FR1138	A	19950831	A61K-039/39	199616
AU 9533490	A	19960322	AU 9533490	A	19950831	A61K-039/39	199626
EP 814835	A1	19980107	EP 95929918	A	19950831	A61K-039/39	199806
			WO 95FR1138	A	19950831		
KR 97705411	A	19971009	WO 95FR1138	A	19950831	A61K-039/39	199841
			KR 97701329	A	19970228		
JP 10509690	W	19980922	WO 95FR1138	A	19950831	A61K-039/00	199848
			JP 96508540	A	19950831		
AU 704633	B	19990429	AU 9533490	A	19950831	A61K-039/39	199928

Priority Applications (No Type Date): FR 9410479 A 19940831

Cited Patents: 3.Jnl.Ref; EP 344040; WO 9420078

Patent Details:

Patent	Kind	Lan	Pg	Filing Notes	Application	Patent
--------	------	-----	----	--------------	-------------	--------

FR 2723849 A1 37

WO 9606638 A1 F 47

Designated States (National): AU CA JP KR US

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LU MC NL
PT SE

AU 9533490 A Based on WO 9606638

EP 814835 A1 F Based on WO 9606638

Designated States (Regional): AT BE CH DE DK ES FR GB GR IE IT LI LU MC
NL PT SE

KR 97705411 A Based on WO 9606638

JP 10509690 W 45 Based on WO 9606638

AU 704633 B Previous Publ. AU 9533490

Based on WO 9606638

Abstract (Basic): FR 2723849 A

Immunogenicity of an antigen (Ag) is increased by stable
 interaction with a particulate vector comprising a non-liq. hydrophilic
 core and an external layer of phospholipid (PL) or fatty acids. (FA).
 Prods. contg. Ag bound to such vectors are also new.

USE - The prods. are useful in vaccines, most esp. against
 cytomegalovirus (CMV).

ADVANTAGE - The prods. are more immunogenic than Ag alone, esp.
 they improve proliferation of CD4 positive T cells, resulting in
 increased secretion of cytokines and expression of surface molecules

required for proliferation and differentiation of antibody producing B cells.

Dwg.0/11

Title Terms: INCREASE; IMMUNOGENIC; ANTIGEN; INTERACT; VECTOR; PARTICLE; SOLID; HYDROPHILIC; CORE; OUTER; LAYER; FATTY; ACID; PHOSPHOLIPID; USEFUL ; VACCINE; CYTOMEGALOVIRUS

Derwent Class: B04

International Patent Class (Main): A61K-039/00; A61K-039/39

International Patent Class (Additional): A61K-009/50; A61K-039/12; A61K-039/245; A61K-047/24; C07K-014/045; C07K-019/00; C12N-015/38; C12N-015/62

File Segment: CPI

Manual Codes (CPI/A-N): B04-B01B; B04-B04C1; B04-C02B; B04-C02X; B04-L04; B04-N0300E; B10-C04E; B14-S11A

Chemical Fragment Codes (M1):

01 M421 M423 M431 M782 M903 V270 V279 V791

Chemical Fragment Codes (M2):

02 B415 B515 B701 B713 B720 B815 B831 G037 G563 H100 H181 H405 H464
H714 H721 H722 H731 J0 J012 J013 J171 J2 J272 L722 M210 M211 M212
M213 M214 M215 M216 M220 M221 M222 M223 M224 M225 M226 M231 M232
M233 M262 M273 M282 M283 M312 M313 M321 M332 M342 M343 M349 M381
M383 M391 M392 M411 M431 M510 M520 M530 M540 M541 M620 M782 M903
M904 N103 V0 V270 V279 V771 9615-06801-M

03 J0 J011 J1 J171 M225 M231 M262 M281 M320 M416 M431 M620 M782 M903
M904 M910 N103 V270 V279 R00121-M

Derwent Registry Numbers: 0121-U

Specific Compound Numbers: R00121-M

Generic Compound Numbers: 9615-06801-M

PA 3054998 v1